SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Inovios FDA approval has lifted optimism about regulatory flexibility for rare-disease therapies, as traders position ahead of Capricors Nov. 22 FDA decision on deramiocel for Duchenne muscular dystrophy. The community is broadly bullish and discussing possible short covering, but claims of an approval leak remain speculation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros quarterly earnings report and outlook are the dominant focus, with traders weighing the companys preliminary revenue update against concerns about margins, cash flow, and whether forward guidance can sustain growth. Bullish traders expect strong results to support a rebound, while skeptics question management credibility and warn that a headline beat may not be enough to restore confidence.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is drawing attention ahead of its quarterly results, with traders focused on forward guidance and data-center demand for AI chips amid concerns raised by Intels weak outlook. Some expect strong results to support a rebound, while others worry that high valuation and recent tech-stock selloffs could weigh on the shares even if AMD beats expectations.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers quarterly results beat expectations and the company raised its full-year outlook, with traders pointing to growth in newer products and cost cuts as signs of a turnaround. The muted-to-negative share reaction has frustrated bulls, while skeptics cite flat overall revenue, declining COVID-related sales and looming patent expirations as reasons for caution.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals strong Rezdiffra growth and first profitable quarter are being overshadowed by a sharp selloff, with traders debating whether continued spending and the prospect of uneven near-term profitability outweigh the launch momentum. Some also question whether a whistleblower-retaliation lawsuit disclosed in the 10-Q is weighing on sentiment, though its role in the decline is uncertain.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

ANET is drawing attention ahead of its quarterly report, with traders focused on whether AI data-center networking demand and hyperscaler spending will support another strong result. Bulls see the pullback as a buying opportunity, while bears point to valuation, uncertain buildout schedules and volatile post-earnings trading.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv shares are rebounding after a third-quarter earnings beat, reaffirmed outlook, expanded cost-savings target and plans to resume share buybacks. Traders welcomed the update as a potential turnaround signal after a steep decline, while skeptics point to weak underlying growth and execution risks.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs quarterly results and decision to maintain its distribution are driving discussion, with traders noting that refinery-hedge losses contributed to the reported loss. The community is split between viewing the steady payout and CVR Energys refinery expansion as supportive, and worrying about IEPs losses and whether the distribution is sustainable.

Toast, Inc. engages in the development and provision of consumer payment application for restaurants. It offers terminals, kiosk, guest facing display, and system accessories. The firm also offers point of sale, reporting and analytics, online ordering and delivery, and kitchen display system. The company was founded by Jonathan Grimm, Aman Narang, and Stephen J. Fredette in December 2011 and is headquartered in Boston, MA.

Toast Inc - Ordinary Shares - Class A

Toast Inc

Toasts earnings are driving discussion: traders cite solid growth, profitability and raised guidance, but the shares sold off, prompting debate over whether expectations were higher and whether weakness in software stocks and AI-related concerns are weighing on sentiment. Some also point to the FTC lawsuit as a regulatory overhang.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm-election uncertainty is dominating discussion, with traders debating whether potential Republican losses could pressure the Trump-linked stock versus election-related optimism behind a relief bounce. Some also cite the TAE Technologies merger, while bearish posts raise concerns about dilution and the companys fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tevas Q3 earnings beat and higher full-year outlook are driving attention, with traders highlighting strong growth in AUSTEDO, AJOVY and UZEDY despite continued pressure on generics. The reaction is broadly bullish, though some note that generics weakness remains a drag on the growth story.

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking 

Equity

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. 


J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down

JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot 

The U.S. Food and Drug Administration approved Weltruza as an extended-release injectable suspension for adults with schizophrenia.

J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.

FDA Approves Teva's Once-Monthly Injectable Olanzapine

(RTTNews) - Friday, Teva Pharmaceuticals (TEVA) announced that the U.S. FDA has approved WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia...

Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) presented new efficacy and safety data for ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist being developed for pediatric patients with Tourette syndrome...

Here's Why You Should Add URGN Stock to Your Portfolio Now

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

$TEVA Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.86 up 10.26% YoY
• Reported revenue of $4.39B down -1.90% YoY
• Teva raised 2026 revenue guidance to $16.7B and non-GAAP diluted EPS guidance to $1.92; free cash flow guidance is $2.1B, with higher outlooks for AUSTEDO, AJOVY and UZEDY.

Stocktwits

Teva- Pharmaceutical Industries Ltd. - ADR

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.86 up 10.26% YoY
• Reported revenue of $4.39B down -1.90% YoY
• Teva raised 2026 revenue guidance to $16.7B and non-GAAP diluted EPS guidance to $1.92; free cash flow guidance is $2.1B, with higher outlooks for AUSTEDO, AJOVY and UZEDY.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $0.86 up 10.26% YoY
• Reported revenue of $4.39B down -1.90% YoY
• Teva raised 2026 revenue guidance to $16.7B and non-GAAP diluted EPS guidance to $1.92; free cash flow guidance is $2.1B, with higher outlooks for AUSTEDO, AJOVY and UZEDY.

Teva's revenue declined amid generic competition; GAAP operating income and diluted EPS were lower year over year, and API sales fell amid lower demand and temporary supply challenges.

Teva's three innovative brands grew 33% to approximately $1.1B, gross margins expanded year over year, WELTRUZA received FDA approval, and ecopipam advanced to NDA review.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd.

Bullish Sentiment

<ul class="summary-bullets"><li>BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A.&nbsp;</li><li>Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale.</li><li>The week marked an extension of a quieter stretch in biotech dealmaking after larger deals in the first half of 2026.</li></ul><p>U.S.-listed drugmakers continued to prefer asset licensing and bankruptcy purchases of drug candidates this week rather than large full-company acquisitions, marking a quieter stretch compared with earlier in 2026, when multi-billion-dollar buyouts of U.S. biotechs dominated.</p><p>This week, rare-disease enzyme therapies and late-stage neuroscience assets drew the most capital as BioMarin and Teva sought to strengthen their positions in certain clinical areas.</p><h2 class="st-heading-2">BioMarin Licenses Long-Acting Fabry Therapy</h2><p>BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease, a rare disorder that causes a fatty substance to build up inside cells and blood vessels.</p><p>BioMarin is paying $70 million upfront. The Korean partners are jointly eligible for up to $405 million in further milestones plus tiered royalties. The candidate is in an early-stage trial and is designed for subcutaneous dosing. BioMarin will lead subsequent global development and commercialization outside Korea.</p><p>The licensing deal reflects BioMarin’s efforts to build a pipeline aimed at Fabry, after its acquisition of Amicus Therapeutics was completed earlier this year. The previous deal brought Amicus’s Galafold, approved for Fabry disease, under BioMarin’s fold.</p><p><a class="mention" data-mention="$BMRN" data-symbol-id="BMRN" href="https://stocktwits.com/symbol/BMRN" target="_blank">BMRN stock</a> gained about 5% this week.</p><h2 class="st-heading-2">Teva Acquires BioXcel Neuroscience Assets</h2><p>Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale. The deal, announced earlier this week, includes worldwide rights to BXCL501, an investigational therapy under FDA review for potential at-home treatment of agitation associated with schizophrenia or bipolar disorder, and the approved hospital product IGALMI. Teva paid $57.5 million upfront and could owe up to $67.5 million in contingent payments tied to regulatory timing and sales milestones.</p><p>The purchase supports Teva’s pivot toward innovative neuroscience assets. Earlier this year, the company also acquired Emalex Biosciences for $700 million upfront to gain its neuroscience candidate ecopipam for the treatment of Tourette syndrome.</p><p>TEVA stock added about 7% this week.</p><h2 class="st-heading-2">The Shift In Dealmaking Approach</h2><p>Earlier in 2026, U.S.-listed buyers deployed substantial capital to fully acquire other U.S. biotechs. Major deals that moved markets included Vertex’s <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-soars-nearly-100-percent-on-vertex-10-billion-acquisition/cZmlGWWR7mT">acquisition</a> of Crinetics, AbbVie’s purchase of Apogee, Gilead’s buyout of Arcellx, and others that together pushed total U.S. biotech <a href="https://stocktwits.com/news-articles/markets/equity/gilead-merck-eli-lilly-lead-106-billion-takeover-wave-in-2026/cZ0FblYRezX">merger and acquisition</a> value well above prior-year levels by the end of the third quarter. Capital also flowed into large licensing packages, particularly for China-originated assets showing potential in immune-system-mediated diseases, cancer, or obesity.</p><p>On Stocktwits, retail sentiment around BMRN was 'neutral' at the time of writing, while sentiment around TEVA was 'neutral.'&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/stocktwits-zero-to-sixty-rivian-beats-q3-estimates-on-r2-strength-and-raises-guidance-tesla-expands-robotaxi-fleet-and-ford-advances-low-cost-ev-plans/cZUKK8sR9cB">Stocktwits Zero To Sixty: Rivian Raises Delivery Guidance On R2 Demand, Tesla Expands Robotaxi Fleet, And Ford Advances Low-Cost EV Plans</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Assortment of colorful tablets, capsules, and softgel supplements arranged in a clean repeating pattern against a minimal background. Source: Getty Images

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. 

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Biomarin Pharmaceutical Inc. - Registered Shares

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits Polls

Strong Q3 performance featuring an EPS of $0.86 and raised full-year revenue guidance to $16.7B-$17.0B continues to lift sentiment.

New deals with Samsung Bioepis for biosimilars and the acquisition of neuroscience assets highlight an expanding and diversifying clinical pipeline.

Traders are eyeing technical breakout levels after the stock hit fresh 52-week highs following recent quarterly results.

Current Price	$41.73
Prev Close	$40.70
Open	$41.91
Dividend Yield	0.00%
50-Day Moving Average	$39.15
Beta	0.78
Avg. Volume	6.2M
PE Ratio	67.86

52-Week High	$42.59
52-Week Low	$20.11
Market Capitalization	$47.43B
EPS (Annual)	$1.21
Price to Book	6.12
Revenue Per Employee	$519,492.59

Feed

News

Sentiment

Earnings

Fundamentals

Info

TEVA Fundamentals